Found 5 matching trials
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors
PHASE1This is a phase I, single-arm, single-center, open-label, dose-escalation S...
Location
Sun Yat-sen University Cancer Center
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
PHASE1This is a phase Ib,single arm,open label study evaluating the safety and ef...
Location
Beijing Cancer Hospital
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
PHASE2This is a phase II, Single-arm,Open-label Study evaluating the safety and e...
Location
Multiple Locations
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
PHASE1The purpose of this study is to evaluate the safety, tolerability, pharmaco...
Location
Hospital of Blood Disease, Chinese Academy of Medical Sciences
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
PHASE1This is a phase Ib, multi-center, open label study evaluating the safety an...
Location
Sun Yat-sen University Cancer Center